Curia and Corning Collaborate to Advance Biopharmaceutical Continuous-Flow Development

Curia announced on March 23, 2023 that it is collaborating with Corning to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally. The collaboration marks the first global installation of Corning’s G1 production system to support higher-quality API-chemical production using flow-chemistry technology.

Continuous flow chemistry is crucial for the development and manufacture of pharmaceutical intermediates and APIs and provides advantages compared with traditional batch processing. It can deliver a faster and more robust material production with a higher selectivity of desired products, according to a company press release. The collaboration will combine Curia’s expertise and global network of facilities with Corning’s continuous flow technology to help drive business efficacies as well as improve patients’ lives.

“Innovation in drug development and production calls for safety at high speed,” said Christopher Conway, president, R&D, Curia, in the release. “The implementation of Corning’s G1 Production Reactor at our Albany facility expands our capability to provide scalable solutions that address complex development and manufacturing requirements facing the pharmaceutical industry. Using advanced technology and standardized workflows, Curia offers continuous flow chemistry from targeted development to commercial scale globally.”